The Journal of clinical endocrinology and metabolism

How Blood Sugar and Body Weight Levels Affect Heart Benefits of Oral Semaglutide in the SOUL Trial

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Oral semaglutide reduced the risk of major adverse cardiovascular events (MACE) by 14% in the SOUL trial.

  • The trial was registered under NCT03914326.
  • The relationship between baseline or changes in HbA1c or BMI and cardiovascular benefits remains unclear.
  • This finding suggests a potential cardiovascular advantage of oral semaglutide.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Mar '26
Oral Semaglutide and Changes in Heart Risk Factors in High-Risk Type 2 Diabetes
top 1% journal
journal article
Feb '26
Oral Semaglutide and Heart Failure Results in People with Type 2 Diabetes
top 2% journal
journal article
Jul '24
Effectiveness and safety of oral semaglutide alone compared to placebo in mostly Chinese adults with type 2 diabetes
top 2% journal
cited by 28 papers
randomized controlled trial
Jun '19
Lowering heart risk with weekly semaglutide in type 2 diabetes: differences by gender, age, and starting heart risk
top 2% journal
cited by 108 papers
research support, non-u.s. gov't
Jan '25
Semaglutide's effects on heart failure with preserved pumping and type 2 diabetes in obesity, varying by starting blood sugar levels
top 1% journal
cited by 16 papers
randomized controlled trial
Mar '25
Oral Semaglutide and Heart Health in People with High-Risk Type 2 Diabetes
🏆 top 0.1% journal
cited by 252 papers
randomized controlled trial
Jun '24
Semaglutide and Heart Health Linked to Starting and Changing Blood Sugar Levels in Overweight or Obese People Without Diabetes
cited by 40 papers
randomized controlled trial
Mar '19
Additional Oral Semaglutide vs Sitagliptin and Their Effects on Blood Sugar Control in Adults with Type 2 Diabetes Not Controlled by Metformin Alone or with Sulfonylurea
cited by 357 papers
randomized controlled trial

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief